News

During a 6-day PSC-to-ectoderm differentiation workflow, FateView™ identified a PSC line diverging from the expected differentiation trajectory around Day 2–3 using label-free imaging. Traditional endpoint immunostaining analysis would not have revealed the divergence until Day 6.

CellVoyant and Pluristyx announce a strategic partnership combining predictive AI and human iPSC technologies for enhanced cell characterisation.

FateView™ introduces label-free colony detection, enabling quantitative analysis of colony count and cell confluence from microscopy images.

FateView™ Cell Detection enables consistent, label-free identification and quantification of cells from imaging data—providing a scalable foundation for earlier and more reliable analysis.

CellVoyant and Automata announce a strategic partnership integrating FateDrive™ with Automata’s LINQ™ platform to enable AI-driven, closed-loop cell culture optimisation.

CellVoyant and Automata demonstrate closed-loop AI-driven cell culture by integrating FateView™ analytics with FateDrive™ optimisation on the LINQ™ platform.

CellVoyant was featured in Fortune magazine in an article by AI Editor Jeremy Kahn, highlighting the company’s vision to transform cell-based therapeutics using AI and the FateView™ technology.

CellVoyant was named the Innovation Incubator Winner for 2025 at the AI Drug Discovery & Development Summit for its work applying AI to label-free live-cell imaging and predictive cell analytics.

FateView™ the first online platform enabling AI-driven, predictive live cell analytics was publicly launch in September with a one-month free trial for new users.

CellVoyant was recognised as a 2024 WIRED Trailblazer.